Effect of high-flow nasal therapy during acute aerobic exercise in patients with chronic obstructive pulmonary disease after exacerbation: protocol for a randomised, controlled, cross-over trial

Guillaume Prieur, Clement Medrinal, Yann Combret, Aurora Robledo Quesada, Fabrice Prieur, Jean Quieffin, Jean Christian Borel, Gregory Reychler, Guillaume Prieur, Clement Medrinal, Yann Combret, Aurora Robledo Quesada, Fabrice Prieur, Jean Quieffin, Jean Christian Borel, Gregory Reychler

Abstract

Introduction: Early pulmonary rehabilitation is recommended after a severe exacerbation of chronic obstructive pulmonary disease (COPD). However, this is difficult to implement, particularly for exercise training. High-flow nasal therapy (HFNT) may reduce the work of breathing and dyspnoea and may improve exercise tolerance.

Methods and analysis: This is a single-centre, prospective, controlled, randomised, cross-over study. Eligible patients will have a diagnosis of COPD (postbronchodilator forced expiratory volume in 1 s/forced vital capacity ratio of <0.7). Two constant work rate exercise tests at 80% of the peak work rate will be carried out on two consecutive days with and without HFNT. The primary outcome will be the difference in endurance time between the two conditions. Secondary outcomes will be the change in muscle oxygenation during exercise, dyspnoea and muscle fatigue, respiratory muscle strength after exercise, respiratory rate, cardiac frequency, transcutaneous CO2 pressure and pulsed O2 saturation. Nineteen patients will be included. Data will be analysed as intention to treat by a blinded statistician.

Ethics and dissemination: Ethics approval has been obtained from the Ethics Committees Nord-Ouest III, Caen, France (N° ID RCB: 2016-A01325-46). The study will begin in April 2017 for a duration of 2 years. The results of the trial will be presented at national and international meetings and published in peer-reviewed journals.

Trial registration number: NCT03058081.

Keywords: COPD; Exercise; High Flow Nasal Therapy; muscle oxygenation; pulmonary rehabilitation.

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Study design. CONSORT, Consolidation Standards of Reporting Trials; WRpeak, peak work rate.

References

    1. Donaldson GC, Seemungal TA, Bhowmik A, et al. . Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847–52.
    1. Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, et al. . Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005;60:925–31.
    1. Spencer S, Calverley PM, Burge PS, et al. . Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004;23:698–702.
    1. de Miranda S, Pochard F, Chaize M, et al. . Postintensive care unit psychological burden in patients with chronic obstructive pulmonary disease and informal caregivers: A multicenter study. Crit Care Med 2011;39:112–8.
    1. Celli BR, Decramer M, Wedzicha JA, et al. . An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. Eur Respir J 2015;45:879–905.
    1. Harrison SL, Robertson N, Graham CD, et al. . Can we identify patients with different illness schema following an acute exacerbation of COPD: a cluster analysis. Respir Med 2014;108:319–28.
    1. Benzo R, Wetzstein M, Neuenfeldt P, et al. . Implementation of physical activity programs after COPD hospitalizations: Lessons from a randomized study. Chron Respir Dis 2015;12:5–10.
    1. Bräunlich J, Köhler M, Wirtz H. Nasal highflow improves ventilation in patients with COPD. Int J Chron Obstruct Pulmon Dis 2016;11:1077–85.
    1. Biselli PJ, Kirkness JP, Grote L, et al. . Nasal high-flow therapy reduces work of breathing compared with oxygen during sleep in COPD and smoking controls: a prospective observational study. J Appl Physiol 2017;122:82–8.
    1. Fraser JF, Spooner AJ, Dunster KR, et al. . Nasal high flow oxygen therapy in patients with COPD reduces respiratory rate and tissue carbon dioxide while increasing tidal and end-expiratory lung volumes: a randomised crossover trial. Thorax 2016;71:759–61.
    1. Cirio S, Piran M, Vitacca M, et al. . Effects of heated and humidified high flow gases during high-intensity constant-load exercise on severe COPD patients with ventilatory limitation. Respir Med 2016;118:128–32.
    1. Brusasco V, Crapo R, Viegi G. Coming together: the ATS/ERS consensus on clinical pulmonary function testing. Eur Respir J 2005;26:1–2.
    1. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111–7.
    1. Hill K, Jenkins SC, Cecins N, et al. . Estimating maximum work rate during incremental cycle ergometry testing from six-minute walk distance in patients with chronic obstructive pulmonary disease. Arch Phys Med Rehabil 2008;89:1782–7.
    1. Kirkham AA, Pauhl KE, Elliott RM, et al. . Utility of equations to estimate peak oxygen uptake and work rate from a 6-minute walk test in patients with COPD in a clinical setting. J Cardiopulm Rehabil Prev 2015;35:431–8.
    1. American Thoracic Society/European Respiratory Society. ATS/ERS statement on respiratory muscle testing. Am J Respir Crit Care Med 2002;166:518–624.
    1. Mador MJ, Rodis A, Magalang UJ. Reproducibility of Borg scale measurements of dyspnea during exercise in patients with COPD. Chest 1995;107:1590–7.
    1. Ries AL. Minimally clinically important difference for the UCSD Shortness of Breath Questionnaire, Borg Scale, and Visual Analog Scale. COPD 2005;2:105–10.
    1. Puente-Maestu L, Palange P, Casaburi R, et al. . Use of exercise testing in the evaluation of interventional efficacy: an official ERS statement. Eur Respir J 2016;47:429–60.
    1. Wellek S, Blettner M. On the proper use of the crossover design in clinical trials: part 18 of a series on evaluation of scientific publications. Dtsch Arztebl Int 2012;109:276–81.
    1. Rubin DB. Multiple imputation for Nonresponse in surveys. John Wiley & Sons, 2004.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться